Zura Bio initiated with a Neutral at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Zura Bio with a Neutral rating and $5 price target. Zura is a clinical stage biotechnology company developing autoimmune disease therapeutics, the analyst tells investors in a research note. The firm says the data for lead asset tibulizumab appears mixed, with Phase 1 PK data not as clear as positive preclinical data.